Erastin: Mechanistic Insights and Benchmarks for Ferroptosis Research

Executive Summary: Erastin (CAS 571203-78-6) is a small molecule that induces ferroptosis, an iron-dependent, non-apoptotic cell death mechanism distinct from apoptosis, necroptosis, and autophagy (Saini et al. 2023). It achieves selectivity by inhibiting the cystine/glutamate antiporter system Xc⁻, leading to glutathione (GSH) depletion and lethal accumulation of lipid peroxides. Erastin is most effective in tumor cells harboring KRAS, HRAS, or BRAF mutations. It is widely used to interrogate oxidative stress pathways and develop precision oncology strategies (APExBIO Erastin B1524). Solutions should be freshly prepared in DMSO and are not stable for long-term storage.

Biological Rationale

Ferroptosis is a regulated cell death process characterized by iron-dependent lipid peroxidation and distinct morphological, biochemical, and genetic features compared to apoptosis (Saini et al. 2023). Tumor cells with RAS or BRAF mutations are often therapy-resistant due to evasion of apoptotic pathways. These cells, however, display increased vulnerability to ferroptosis, making it a promising therapeutic target in oncology. The cystine/glutamate antiporter (system Xc⁻), encoded by SLC7A11, imports cystine required for GSH synthesis, a critical antioxidant. Inhibiting system Xc⁻ disrupts redox homeostasis, sensitizing cancer cells to oxidative damage. This is especially relevant for colorectal, breast, and other solid tumors with high mutational burden in the RAS-RAF-MEK signaling pathway (Saini et al. 2023).

Mechanism of Action of Erastin

Erastin exerts its effects through dual mechanisms. First, it directly binds and modulates voltage-dependent anion channels (VDAC) on mitochondria, disrupting metabolic flux. Second, it inhibits system Xc⁻, preventing cystine import and glutamate export. The resulting cystine deprivation leads to rapid depletion of intracellular GSH. In the absence of GSH, glutathione peroxidase 4 (GPx4) activity is compromised, and lipid peroxides accumulate, triggering ferroptosis (Saini et al. 2023). Erastin's specificity for tumor cells with KRAS or BRAF mutations arises from their increased reliance on antioxidant pathways and altered redox balance (see: Selective Ferroptosis Inducer Targeting RAS/BRAF…—this article further details Erastin’s unique selectivity and extends the mechanistic discussion presented there).

Evidence & Benchmarks

• Treatment of HT-1080 fibrosarcoma cells with Erastin at 10 μM for 24 hours induces ferroptosis as measured by lipid peroxidation and cell viability assays (APExBIO product sheet).
• System Xc⁻ inhibition leads to GSH depletion, diminished GPx4 activity, and iron-dependent accumulation of lipid peroxides—hallmarks of ferroptosis (Saini et al. 2023).
• PERK loss downregulates SLC7A11 (system Xc⁻), promoting ferroptosis and limiting in vivo colorectal tumor growth (Saini et al. 2023).
• Therapy-resistant tumor cells are more sensitive to ferroptosis, offering a rationale for targeting apoptosis-resistant cancers (Saini et al. 2023).
• Erastin is insoluble in water and ethanol, but soluble in DMSO at ≥10.92 mg/mL with gentle warming (APExBIO).

Applications, Limits & Misconceptions

Erastin is primarily used to study ferroptosis in cancer biology, oxidative stress assays, and drug resistance models. Its selectivity for RAS/BRAF-mutant tumor cells allows for targeted mechanistic studies and screens for combination therapies. The compound is also valuable for dissecting the role of system Xc⁻, GPx4, and lipid peroxidation dynamics.

For a broader mechanistic context—including links to sphingolipid metabolism and the HIF-1 pathway—see Erastin and the Next Frontier of Ferroptosis…. The present article emphasizes verifiable benchmarks and practical parameters, extending the strategic guidance offered previously.

Common Pitfalls or Misconceptions

• Erastin does not induce apoptosis or necroptosis; its cell death mechanism is caspase-independent and iron-dependent (Saini et al. 2023).
• It is ineffective in cells lacking functional iron metabolism or in models insensitive to system Xc⁻ inhibition.
• Long-term storage of Erastin solutions is not recommended; compound should be freshly prepared in DMSO for each experiment (APExBIO).
• Erastin is not water or ethanol soluble; improper solvent use leads to precipitation and unreliable dosing.
• Ferroptosis induction by Erastin can be blocked by iron chelators or lipophilic antioxidants, which should be controlled for in experiments.

Workflow Integration & Parameters

For ferroptosis assays, Erastin (SKU B1524) is typically dissolved in DMSO (≥10.92 mg/mL, gentle warming), aliquoted, and used at 10 μM final concentration for 24 hours in standard cell culture models (e.g., HT-1080, engineered RAS/BRAF mutant tumor lines) (APExBIO). Compound is supplied as a solid (MW 547.04, C30H31ClN4O4); store at -20°C in desiccated conditions. Avoid repeated freeze-thaw cycles. For oxidative stress assays, include positive (e.g., RSL3) and negative (e.g., ferrostatin-1, iron chelator) controls. For experimental troubleshooting, see Erastin (B1524): Scenario-Driven Solutions for Reliable F…, which provides guidance on achieving reproducible results—this article adds specific solvent and workflow parameters for high-confidence ferroptosis induction.

Conclusion & Outlook

Erastin remains a cornerstone tool for ferroptosis and oxidative cell death research, particularly in cancer models with RAS or BRAF mutations. Its mechanism—targeting system Xc⁻ and VDAC—offers both mechanistic specificity and translational relevance. As APExBIO continues to refine Erastin’s utility and documentation, researchers are empowered to design robust, reproducible experiments. Future directions include combinatorial therapy screening and advanced profiling in therapy-resistant tumors (Saini et al. 2023). For foundational background and advanced mechanistic perspectives, see Erastin: Ferroptosis Inducer for Advanced Cancer Biology…, which this article updates with the latest quantitative benchmarks and workflow integration advice.